Estrella Mountain Dialysis, Llc (ARA) is a medicare approved dialysis facility center in Phoenix, Arizona and it has 18 dialysis stations. It is located in Maricopa county at 9250 West Thomas Road, Phoenix, AZ, 85037. You can reach out to the office of Estrella Mountain Dialysis, Llc (ARA) at (623) 772-7363. This dialysis clinic is managed and/or owned by American Renal Associates. Estrella Mountain Dialysis, Llc (ARA) has the following ownership type - Profit. It was first certified by medicare in March, 2013. The medicare id for this facility is 032639 and it accepts patients under medicare ESRD program.
| Name | Estrella Mountain Dialysis, Llc (ARA) |
|---|---|
| Location | 9250 West Thomas Road, Phoenix, Arizona |
| No. of Dialysis Stations | 18 |
| Medicare ID | 032639 |
| Managed By | American Renal Associates |
| Ownership Type | Profit |
| Late Shifts | No |
| 9250 West Thomas Road, Phoenix, Arizona, 85037 | |
| (623) 772-7363 | |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
| NPI Number | 1063767739 |
| Doing Business As | Estrella Mountain Dialysis Llc |
| Address | 9250 W Thomas Rd Phoenix, Arizona, 85037 |
| Phone Number | (623) 772-7363 |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 84% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 6% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 10% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 80% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 20% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 0% | 14% |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 65% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 15% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 20% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 71% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 22% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 7% | 12% |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 88% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 12% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 83% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 8% | 12% |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 27 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 37 |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 74 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 732 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
| Adult patients getting regular peritoneal dialysis at the center | 6 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 54 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Estrella Mountain Dialysis, Llc (ARA) with elevated calcium levels.
| Patients with hypercalcemia | 81 |
| Hypercalcemia patient months | 802 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 83 |
| Patients with Serumphosphor less than 3.5 mg/dL | 3 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 22 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 28 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 30 |
| Patients with Serumphosphor greater than 7 mg/dL | 17 |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 46 |
| Patient months included in arterial venous fistula and catheter summaries | 423 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 77 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 8 |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 64 |
| Hospitalization Rate in facility | 196.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 343.5 |
| Hospitalization Rate: Lower Confidence Limit | 116.9 |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Estrella Mountain Dialysis, Llc (ARA) were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 26.5 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 38.6 |
| Readmission Rate: Lower Confidence Limit | 16.7 |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Estrella Mountain Dialysis, Llc (ARA) get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .65 (As Expected) |
| SIR: Upper Confidence Limit | 1.78 |
| SIR: Lower Confidence Limit | .17 |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Estrella Mountain Dialysis, Llc (ARA)'s rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 50 |
| Transfusion Rate in facility | 28.7 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 168 |
| Transfusion Rate: Lower Confidence Limit | 6.1 |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at Estrella Mountain Dialysis, Llc (ARA) lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 284 |
| Mortality Rate in facility | 17.2 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 25 |
| Mortality Rate: Lower Confidence Limit | 11.3 |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago
Maricopa Medical Ctr - Dialysis Location: 2525 E Roosevelt St, Phoenix, Arizona, 85008 Phone: (602) 344-1601 |
South Phoenix Dialysis Services (FMC) Location: 1021 S 7th Ave Ste 108, Phoenix, Arizona, 85007 Phone: (602) 253-1954 |
Desert Valley Dialysis (FMC) Location: 15846 N Cave Creek Rd Ste 2, Phoenix, Arizona, 85032 Phone: (602) 971-4555 |
Estrella Dialysis Center (FMC) Location: 5546 W Roosevelt St Ste 1, Phoenix, Arizona, 85043 Phone: (602) 352-0724 |
News Archive
A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.
Recent state developments include a pending tax on hospitals in California, resistance to health system change in the Missouri medical community and a proposed tax on physician fees in Michigan.
Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.
› Verified 2 days ago